Results 71 to 80 of about 5,292 (260)
Tiotropium in asthma: back to the future of anticholinergic treatment
Clinical and Molecular Allergy, 2017 Asthma is among the most common chronic diseases worldwide; however, despite progresses in the understanding of the patho-physiological mechanisms and advances in the development of new therapeutic options and strategies, the disease remains uncontrolled
Matteo Bonini, Nicola Scichilone
doaj +1 more source
The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease [PDF]
, 2015 Background: This study investigated the effects on 24-h lung function and lung volume of a once-daily fixed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium and the long-acting beta(2)-agonist olodaterol in patients with chronic
Beeh, Kai-Michael +7 more
core +2 more sources
Therapy and control of bronchial asthma in children and adolescents
Медицинский совет, 2020 Up to 22% of the population in the world suffer from bronchial asthma according to the data from different regions and sources. This is about 358 million people.
T. N. Surovenko, E. F. Glushkova
doaj +1 more source
Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. [PDF]
, 2011 BACKGROUND: Interactions between spirometry and patient-reported outcomes in COPD are not well understood. This systematic review and study-level analysis investigated the relationship between changes in FEV1 and changes in health status with ...
Bourbeau, J +5 more
core +1 more source
British Journal of Pharmacology, Volume 182, Issue 11, Page 2487-2502, June 2025.Background and Purpose Hyoscine butylbromide (HBB) has a low oral (PO) bioavailability. Further, limited data on its activity on non‐gastrointestinal (GI) smooth muscle spasms after oral dosing are available, causing its effects beyond the GI tract to be questioned.
Sara Traserra +4 more
wiley +1 more source
Acetylcholine-treated murine dendritic cells promote inflammatory lung injury [PDF]
, 2019 In recent years a non-neuronal cholinergic system has been described in immune cells, which is often usually activated during the course of inflammatory processes. To date, it is known that Acetylcholine (ACh), a neurotransmitter extensively expressed in
Alcain, Julieta María +8 more
core +1 more source
Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
Respiratory Research, 2020 Background Bronchodilators are the mainstay of pharmacological treatment in chronic obstructive pulmonary disease (COPD), and long-acting muscarinic antagonist (LAMA) monotherapy is recommended as initial treatment for Global Initiative for Chronic ...
Antonio Anzueto, Marc Miravitlles
doaj +1 more source
Recoiling DNA Molecule: Simulation & Experiment [PDF]
Physica A 345, 173-184 (2005), 2002 Single molecule DNA experiments often generate data from force versus extension measurements involving the tethering of a microsphere to one end of a single DNA molecule while the other is attached to a substrate. We show that the persistence length of single DNA molecules can also be measured based on the recoil dynamics of these DNA-microsphere ...
arxiv +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Increased contractility of human airway smooth muscle (hASM) is a hallmark of asthma and chronic obstructive pulmonary disease (COPD). Developing new classes of bronchodilators has proved to be challenging because of efficacy and safety concerns.
Paola Rogliani +4 more
wiley +1 more source
Tiotropium: a new therapeutic option in asthma
Monaldi Archives for Chest Disease, 2013 Tiotropium: a new therapeutic option in asthma. F. Novelli, F. Costa, M. Latorre, L. Malagrinò, A. Celi, B. Vagaggini, P. Paggiaro. Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic ...
F. Novelli +6 more
doaj +1 more source